Zihai Li, Professor and Founding Director at the Pelotonia Institute for Immuno-Oncology, shared a post on LinkedIn about a recent article he and colleagues authored:
“Drug discovery is a lengthy process, and it is especially challenging in academia.
It is the strong conviction, rich science, and the incredible commitment of many that make it possible.
Our approach to targeting the latent TGF-beta-docking/activating receptor GARP is an example of this. Our first-in-human anti-GARP CAR-T trial for patients with relapsed GBM is actively enrolling patients. The preclinical work was published recently in Neuro-Oncology.”
Title: Targeting TGFβ docking receptor Glycoprotein A Repetitions Predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma
Authors: Bill Xingjun Wu, Daniel Kreatsoulas, Hakan Cam, Chelsea Bolyard, Yuzhou Chang, Jay Mandula, Parker W. Welsh, Ziyu Wang, Anqi Li, Payton Weltge, J. Bradley Elder, Pierre Giglio, Jose J. Otero, Prajwal Rajappa, Damien Gerald, Dongjun Chung, Qin Ma, Maria Velegraki, Zihai Li
Read the Full Article.
More posts featuring Zihai Li on OncoDaily.